Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.
Epistemonikos ID: 0bc4a3b9ef3450d9b4bd051b0e2cd5026444de57
First added on: Oct 02, 2023